<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01876589</url>
  </required_header>
  <id_info>
    <org_study_id>VANISH</org_study_id>
    <nct_id>NCT01876589</nct_id>
  </id_info>
  <brief_title>Impact of Vascular Reparative Therapy on Vasomotor Function and Myocardial Perfusion:a Randomized H215O PET/CT Study</brief_title>
  <acronym>VANISH</acronym>
  <official_title>Impact of Vascular Reparative Therapy on Vasomotor Function and Myocardial Perfusion: a Randomized H215O PET/CT Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the improvement of myocardial blood flow induced by&#xD;
      regained vasomotor functions of the stented coronary segment after resorption of BVS over&#xD;
      time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective The objective of the proposed study is to determine the impact of VRT, in&#xD;
      comparison with conventional drug-eluting stenting, on endothelium dependent vasodilation and&#xD;
      maximal hyperemic myocardial perfusion using H215O PET.&#xD;
&#xD;
      Study design The study is designed as a single center single-blind randomized clinical trial&#xD;
      and will be conducted at the VU University Medical Center in Amsterdam.&#xD;
&#xD;
      Summary of the study design It is hypothesized that VRT will result in augmented endothelium&#xD;
      dependent coronary vasodilation and maximal myocardial perfusion as compared with&#xD;
      conventional stenting of a coronary lesion. Within one year sixty patients (age 18-65) with&#xD;
      documented single vessel CAD (type A or B1 lesion) accepted for PCI based on clinical grounds&#xD;
      and according to current international guidelines, will be asked to participate in this&#xD;
      trial. Patients will be randomized to implantation of a drug-eluted stent (Xience Prime) or&#xD;
      BRS (Absorb). The patients will be blinded to the nature of the implanted device. H2 15O PET&#xD;
      will be performed one month (reference scan), one year, and three years after the PCI&#xD;
      procedure (resolution of BRS is generally complete within a three year period). The PET&#xD;
      protocol will consist of three MBF measurements: resting MBF, during endothelial dependent&#xD;
      vasodilation provoked by coldpressor-testing (CPT), and during (endothelial dependent and&#xD;
      independent) maximal vasodilation by infusion of adenosine intravenously. After three years a&#xD;
      control invasive coronary angiogram will document any potential obstructive coronary lesions&#xD;
      that may affect the MBF measurements.&#xD;
&#xD;
      Primary study parameters/outcome of the study MBF measurements: resting MBF, during&#xD;
      endothelial dependent vasodilation provoked by cold-pressor-testing (CPT), and during&#xD;
      (endothelial dependent and independent) maximal vasodilation by infusion of adenosine&#xD;
      intravenously&#xD;
&#xD;
      Secondary study parameters/outcome of the study Obstructive coronary lesions on control&#xD;
      invasive coronary angiogram that may affect the MBF measurements.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Myocardial Blood Flow over time</measure>
    <time_frame>Three years</time_frame>
    <description>Endothelial dependent vasomotor function and effect on myocardial perfusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Restenosis</measure>
    <time_frame>Three years</time_frame>
    <description>Obstructive coronary lesions and lumen dimensions on control invasive coronary angiogram that may affect the MBF measurements</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Bioresorbable vascular scaffold</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paritcipants will receive a bioresorbable vascular scaffols (BVS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xience Prime</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participant will receive a Xience Prime stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bioresorbable vascular scaffold</intervention_name>
    <description>Drug eluting coronary stent, resorbable in 2-3 years</description>
    <arm_group_label>Bioresorbable vascular scaffold</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xience Prime</intervention_name>
    <description>Drug eluting metallic stent</description>
    <arm_group_label>Xience Prime</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with documented obstructive CAD by invasive coronary angiography resulting in&#xD;
             myocardial ischemia (either documented by invasive (i.e. fractional flow reserve, FFR)&#xD;
             or noninvasive imaging techniques (e.g. exercise ECG, myocardial perfusion imaging, or&#xD;
             inducibility of wall motion abnormalities during dobutamine stress).&#xD;
&#xD;
          -  Presence of a single, de-novo lesion in a native coronary artery (type A or B1), with&#xD;
             a reference vessel diameter of at least 3.0 mm and a diameter stenosis of 50% or more&#xD;
             and less than 100%, with a thrombolysis in myocardial infarction (TIMI) flow grade of&#xD;
             at least 2. Coronary lesion must be amendable for successful treatment with one of the&#xD;
             following BRS device dimensions: length 18 or 28 mm, diameter 3.0 or 3.5 mm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age of 65 or above&#xD;
&#xD;
          -  refusal or inability to provide written informed consent&#xD;
&#xD;
          -  other than single CAD&#xD;
&#xD;
          -  abnormal echocardiographic findings (i.e. wall motion abnormalities, ventricular&#xD;
             hypertrophy, valvular disease etc.)&#xD;
&#xD;
          -  complex coronary lesion characteristics (e.g. lesions located in the left main&#xD;
             coronary artery, lesions involving a side branch more than 2 mm in diameter, and the&#xD;
             presence of thrombus or another clinically significant stenosis in the target vessel)&#xD;
&#xD;
          -  poor kidney function defined as an eGFR &lt; 30 ml/min&#xD;
&#xD;
          -  astma or chronic obstructive pulmonary disease&#xD;
&#xD;
          -  other than sinus rhythm&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  bail out stenting after placement of the study device&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Knaapen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>June 10, 2013</study_first_submitted>
  <study_first_submitted_qc>June 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2013</study_first_posted>
  <last_update_submitted>July 30, 2016</last_update_submitted>
  <last_update_submitted_qc>July 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>Wynand Stuijfzand</investigator_full_name>
    <investigator_title>Drs</investigator_title>
  </responsible_party>
  <keyword>Coronary Artery Disease (CAD)</keyword>
  <keyword>Invasive coronary angiography (ICA)</keyword>
  <keyword>Positron Emission Tomography (PET)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

